There are currently 512 ongoing clinical trials involving Bladder Cancer
Of the 512 trials,179 trials are in Phase II
Furthermore, 130 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Bladder Cancer, an oncology condition. The largest number of ongoing clinical trials for Bladder Cancer is conducted in North America. Asia-Pacificand Europe are among some of the other prominent regions involved in Bladder Cancer-related drug trials.
National Cancer Institute US: The leading ongoing Bladder Cancer related clinical trial sponsor
National Cancer Institute US, is the top sponsor for Bladder Cancer-related ongoing clinical trials.
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb Co, Hoosier Cancer Research Network, University of Texas MD Anderson Cancer Center, and Johnson & Johnson are among other notable clinical trial sponsors involved in Bladder Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Bladder Cancer
Pembrolizumab (Keytruda), Capecitabine (Xeloda, Xubix), and Pegylated liposomal doxorubicin (Doxil, Caelyx) are among the key marketed drugs involving Bladder Cancer.
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Keytruda is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Keytruda is marketed for the treatment of Bladder Cancer and several other indications includingEsophageal Squamous Cell Carcinoma (ESCC), Bile Duct Cancer (Cholangiocarcinoma), Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Esophageal Cancer, Adenocarcinoma of The Gastroesophageal Junction, Cervical Cancer, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Head and Neck Cancer, and Gastric Cancer. Pembrolizumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Merck & Co Inc and its subsidiaries.
Capecitabine (Xeloda, Xubix) is a fluoropyrimidine carbamate with antineoplastic activity. It functions via Thymidylate Synthase (TYMS or EC 2.1.1.45) Inhibitor mechanism of action. Capecitabine is formulated in the form of film-coated tablets for oral administration. Capecitabine is marketed for the treatment of Bladder Cancer and several other indications including Breast Cancer, Esophageal Cancer, Adenocarcinoma of The Gastroesophageal Junction, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Colon Cancer, Metastatic Colorectal Cancer, and Rectal Cancer. Capecitabine was first approved in 1998 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by F. Hoffmann-La Roche Ltd and its subsidiaries.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward